<DOC>
	<DOCNO>NCT00009997</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining monoclonal antibody therapy combination chemotherapy may effective treatment locally advance breast cancer . PURPOSE : Phase I trial study effectiveness trastuzumab plus paclitaxel follow surgery combination chemotherapy treat woman locally advance breast cancer .</brief_summary>
	<brief_title>Trastuzumab Chemotherapy Followed Surgery Combination Chemotherapy Treating Women With Locally Advanced Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety toxicity preoperative trastuzumab ( Herceptin ) paclitaxel follow postoperative doxorubicin cyclophosphamide woman locally advance breast cancer HER2 overexpression . II . Determine tumor response patient treat regimen . III . Assess effect regimen tumor histology potential molecular determinant response patient . OUTLINE : Patients receive trastuzumab ( Herceptin ) IV 30-90 minute follow paclitaxel IV 60 minute day 1 . Treatment continue every 7 day total 10 course absence disease progression unacceptable toxicity . Patients undergo modify radical mastectomy lumpectomy axillary node dissection . Beginning 14 day surgery , patient receive doxorubicin IV cyclophosphamide IV 15-30 minute day 1 . Treatment repeat every 21 day total 4 course . After completion chemotherapy , patient hormone receptor-positive disease receive oral tamoxifen daily 5 year . Patients follow 6 month . PROJECTED ACCRUAL : A total 15 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Palpable primary breast cancer least 3 cm ( T2 least 3 cm , T3T4 , N ) No distant metastasis ( M0 ) HER2 overexpression 2+ 3+ immunohistochemistry perform core biopsy specimen use Dako Hercep Test Hormone receptor status : Status know PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal Status : Premenopausal postmenopausal Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 150,000/mm3 Hemoglobin least 10 g/dL Hepatic : Bilirubin great 2.0 mg/dL SGOT/SGPT great 3 time normal Renal : Creatinine great 2.0 mg/dL Cardiovascular : Ejection fraction normal MUGA No history congestive heart failure , myocardial infarction , arrhythmia , ischemic heart disease Other : No prior malignancy except basal cell carcinoma skin carcinoma situ cervix Not pregnant nursing Fertile patient must use effective barrier contraception 2 month study No preexist clinically significant peripheral neuropathy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>